Benorylate: a report on 2 years' experience of its use in rheumatoid arthritis and other chronic rheumatic diseases.
52 outpatients with rheumatoid arthritis or osteoarthritis were given benorylate (as the 40% suspension) in doses of up to 8 g daily. Peroids of medication were varied but some patients were given the drug for nearly 2 years. Assessments of clinical progress were made at regular intervals by recording both subjective and objective measurements including duration of morning stiffness, grip strength, joint size. Laboratory investigations include renal function tests, liver function tests, blood picture and occult blood. No serious side effect, attributable to benorylate was reported and it was concluded that the drug is satisfactory for the long term treatment of rheumatic diseases.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001799:Blood Sedimentation; D004341:Drug Evaluation; D004415:Dyspepsia / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010003:Osteoarthritis / Q000188:drug therapy*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*; D014508:Urea / Q000097:blood; D014839:Vomiting / Q000139:chemically induced
D012459:Salicylates; D014508:Urea